Trial Profile
A Phase 1 Study of the Oral TRK Inhibitor Larotrectinib in Adult Patients With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2023
Price :
$35
*
At a glance
- Drugs Larotrectinib (Primary)
- Indications Adenocarcinoma; Carcinoma; Lung cancer; Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions; First in man
- Sponsors Bayer; Loxo Oncology
- 24 Oct 2023 Results of a pooled analysis from three clinical studies: NCT02576431, NCT02122913, NCT02637687 ; assessing updated efficacy and safety data in an expanded dataset of patients with longer follow-up presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Results of an efficacy analysis from three clinical studies (NCT02576431, NCT02122913, NCT02637687) including treatment-naive non-primary CNS TRK fusion cancer patients from these trials presented at the 48th European Society for Medical Oncology Congress
- 28 Sep 2023 Results of subset analysis (As of data cutoff was July 20, 2021 from three clinical trials NCT02637687 (SCOUT), and NCT02576431 (NAVIGATE), including this trial) evaluating the efficacy and safety of larotrectinib in an expanded data set of adult patients with TRK fusion sarcomas with longer follow-up, published in the Cancer.